Application of Cuscutaamine and / or 19α-hydroxyasiatic acid
By applying dodder extract and 19α-hydroxyasiatic acid to Bazibu Shen capsules, the problem of insufficient quality control research was solved, and a significant anti-osteoporosis effect was achieved. As its quality marker, it promotes osteoblast differentiation and inhibits osteoclast differentiation.
Patent Information
- Application Number
- CN202411263432.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2044-09-10
AI Technical Summary
There is a serious lack of research on the quality control of Bazibu Shen Capsules, and no reports have been found on the evaluation of their anti-osteoporosis bioactivity, which hinders the research on their quality control.
Cuscutaamine and/or 19α-hydroxyasiatic acid were used as quality markers for Bazibu Shen capsules to prepare drugs that promote osteoblast differentiation, promote bone calcification nodules, inhibit osteoclast differentiation, and prepare anti-osteoporosis drugs.
Cuscutaamine and 19α-hydroxyasiatic acid significantly promoted osteoblast differentiation and osteocalcification nodule formation in mouse cell models, and significantly inhibited osteoclast differentiation, exhibiting significant anti-osteoporosis activity and can serve as quality markers for Bazibu Shen capsules.
Smart Images

Figure BDA0005036460200000081 
Figure BDA0005036460200000091 
Figure BDA0005036460200000092
Abstract
Description
Technical Field
[0001] This invention relates to the field of detection of active ingredients in traditional Chinese medicine, and particularly to the application of dodderamine and / or 19α-hydroxyasiatic acid. Background Technology
[0002] Traditional Chinese medicine (TCM) plays a vital role in disease prevention and treatment, thus gaining increasing attention and recognition globally. The quality of TCM directly impacts clinical efficacy and hinders its modernization. However, the complexity of its chemical composition and the ambiguity of its active ingredients pose significant obstacles to TCM quality control. In exploring strategies, Liu et al. proposed the concept of quality biomarkers. This concept focuses on the measurability, specificity, transferability, efficacy, and traceability of TCM quality biomarkers. Characterization of quality biomarkers involves integrating multiple properties, including component analysis, content determination, pharmacokinetics, and network pharmacology. A wide variety of plant secondary metabolites exist in TCM, and components with different structures may possess different biological activities. Therefore, TCM quality biomarkers need to consider the different structural types of various components, which is crucial for quality control based on traditional efficacy. Furthermore, network pharmacology is increasingly being used to elucidate the mechanisms of action between active ingredients and disease therapeutic targets. Currently, the screening of quality biomarkers using network pharmacology primarily focuses on the association between individual compounds and disease targets, without highlighting the mechanism by which multiple TCM components, in combination, cover multiple targets to exert pharmacological effects. Furthermore, the metabolism of Chinese herbal medicine (TCM) components in vivo leads to changes in their biological activity, making the in vivo processes of TCM components particularly important for identifying quality biomarkers. It is well known that TCM formulas are characterized by multiple components, multiple targets, and holistic regulation; however, reports on mining TCM quality biomarkers from a holistic perspective are currently scarce. Therefore, this study proposes a digital and holistic strategy to mine quality biomarkers of absorbable components in Bazibu Shen capsules in different compositional forms, reflecting the structural and holistic diversity of biological pathways.
[0003] Bazibu Shen Capsules (BZBS) are a traditional Chinese medicine compound composed of sixteen single herbs, including Cuscuta chinensis, Lycium barbarum, Schisandra chinensis, Cnidium monnieri, Rosa laevigata, Rubus idaeus, Melia toosendan, Allium tuberosum, Epimedium brevicornu, Morinda officinalis, Cistanche deserticola, Rehmannia glutinosa, Achyranthes bidentata, Panax ginseng, Cervus nippon, and Hippocampus. Clinically, it is used to prevent and treat symptoms such as lower back and knee pain, dizziness, tinnitus, and fatigue caused by kidney yang deficiency. Recent pharmacological studies have shown that Bazibu Shen Capsules can significantly improve bone morphology in D-galactose and NaNO2-induced aged mice and increase the mineral content in their bone tissue. Furthermore, Bazibu Shen Capsules can also improve the bone microstructure of the distal tibia in ovariectomized osteoporosis model rats. Numerous studies have reported that various single herbs in Bazibu Shen Capsules, such as Cuscuta chinensis, Lycium barbarum, Cnidium monnieri, Epimedium brevicornu, Ginseng, Cistanche deserticola, and Rehmannia glutinosa, can improve bone microstructural parameters in ovariectomized osteoporosis models in rats / mice. In conclusion, Bazibu Shen Capsules have a significant anti-osteoporosis effect. While the efficacy of Bazibu Shen Capsules is definite, research on its quality control is severely lacking. Therefore, identifying quality markers for Bazibu Shen Capsules to improve its quality control level is urgently needed.
[0004] It is worth noting that Bazibu Shen Capsules are a complex system composed of 16 single herbs, and no reports have been found on its anti-osteoporosis bioactivity evaluation, which seriously hinders the quality control research of Bazibu Shen Capsules. Summary of the Invention
[0005] In view of this, the present invention provides the application of cuscutamine and / or 19α-hydroxyasiatic acid. Experimental results show that cuscutamine and 19α-hydroxyasiatic acid have anti-osteoporosis activity.
[0006] To achieve the above-mentioned objectives, the present invention provides the following technical solution:
[0007] In a first aspect, the present invention provides the use of dodderamine and / or 19α-hydroxyasiatic acid in the preparation of a drug that promotes osteoblast differentiation.
[0008] In some specific embodiments of the present invention, the effective concentration of dodderamine is 10. -6 M, the effective concentration of the 19α-hydroxyasiatic acid is 10. -6 M. In some specific embodiments of the present invention, the effective concentration of the 19α-hydroxyasiatic acid is 10. -6 and 10 -5 M.
[0009] Secondly, the present invention also provides the use of dodderamine and / or 19α-hydroxyasiatic acid in the preparation of a medicament that promotes bone calcification nodules.
[0010] In some specific embodiments of the present invention, the effective concentration of dodderamine is 10. -6 M.
[0011] Thirdly, the present invention also provides the use of dodderamine and / or 19α-hydroxyasiatic acid in the preparation of drugs that inhibit osteoclast differentiation.
[0012] In some specific embodiments of the present invention, the inhibition of osteoclast differentiation includes reducing the number of multinucleated TRAP-positive cells.
[0013] In some specific embodiments of the present invention, the effective concentration of dodderamine is 10. -5 M, the effective concentration of the 19α-hydroxyasiatic acid is 10. -7 M. In some specific embodiments of the present invention, the effective concentration of the 19α-hydroxyasiatic acid is 10. -7 and 10 -6 M.
[0014] Fourthly, the present invention also provides the use of dodderamine and / or 19α-hydroxyasiatic acid in the preparation of anti-osteoporosis drugs.
[0015] In some specific embodiments of the present invention, the anti-osteoporosis includes:
[0016] (I) Promotes osteoblast differentiation;
[0017] (II) Promotes bone calcification nodules; and / or
[0018] (III) Inhibits osteoclast differentiation;
[0019] The effective concentration of the dodderamine and / or the 19α-hydroxyasiatic acid is 10. -7 M~10 -5 M.
[0020] Fifthly, the present invention also provides the use of dodderamine and / or 19α-hydroxyasiatic acid as quality markers for Bazibu Shen capsules in the preparation of drugs for treating osteoporosis.
[0021] This invention evaluated the anti-osteoporosis effects of cuscutamine and 19α-hydroxyasiatic acid in mouse MC3T3-E1 cells and their osteoclast differentiation (ALP) and mineralization (Alizarin Red stained calcified nodules) using osteoblast differentiation (ALP) and mineralization (Alizarin Red stained calcified nodules). (Number of TRAP-positive cells) in sRANKL-induced mouse RAW 264.7 macrophages. Figure 2 As shown, cuscutamine (10 -6M),19α-hydroxyasiatic acid(10 -6 and 10 -5 M) significantly promoted ALP activity (P<0.05). For example... Figure 3 A and Figure 3 As shown in Figure B, cuscutamine at 10⁻⁶ M significantly promoted the formation of calcified osteocalcified nodules (P<0.05). Figure 4 A and Figure 4 As shown in B, cuscutamine (10 -5 M), 19α-hydroxyasiatic acid(10 -7 and 10 -6 M) significantly reduced the number of multinucleated TRAP-positive cells (P<0.05). These results indicate that cuscutamine and 19α-hydroxyasiatic acid possess anti-osteoporosis activity in osteoblast or osteoclast activity evaluation systems. Cuscutamine and 19α-hydroxyasiatic acid can serve as quality markers for the anti-osteoporosis effects of Bazibu Shen capsules. Attached Figure Description
[0022] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the description of the embodiments or the prior art will be briefly introduced below.
[0023] Figure 1 The extracted ion chromatograms of the original compound (A / B) and metabolites (C / D) in rat plasma after oral administration of BZBS are shown; where (A) and (B) are extracted ion chromatograms of the original compound in rat plasma after oral administration of BZBS; and (C) and (D) are extracted ion chromatograms of the metabolites in rat plasma after oral administration of BZBS.
[0024] Figure 2 The figure shows the effects of different concentrations of cuscutamine and 19α-hydroxyasiatic acid on the differentiation activity of MC3T3-E1 cells; Ctrl represents the blank control group; 17β-E2 represents 17β-estradiol; cuscutamine represents cuscutamine; 19α-hydroxyasiatic acid represents 19α-hydroxyasiatic acid; * indicates a significant difference between the concentration group and the blank control group, ** indicates a highly significant difference between the concentration group and the blank control group;
[0025] Figure 3The figure shows the effects of different concentrations of cuscutamine and 19α-hydroxyasiatic acid on the mineralization activity of MC3T3-E1 cells; where A is a bar chart of calcium nodule staining using the Alizarin Red method; B is a representative image of calcium nodule staining using the Alizarin Red method; Ctrl is the blank control group; 17β-E2 is 17β-estradiol; cuscutamine is cuscutamine; 19α-hydroxyasiatic acid is 19α-hydroxyasiatic acid; * indicates that the concentration group is significantly different from the blank control group, and ** indicates that the concentration group is highly significantly different from the blank control group.
[0026] Figure 4 The results show the effects of different concentrations of cuscutamine and 19α-hydroxyasiatic acid on the differentiation activity of osteoclasts; where A is a bar chart of TRAP-positive multinucleated osteoclasts; B is a representative image of TRAP-positive multinucleated osteoclasts; NS is the negative control group; Ctrl is the blank control group; cuscutamine is cuscutamine; 19α-hydroxyasiatic acid is 19α-hydroxyasiatic acid; * indicates that the concentration group is significantly different from the blank control group; ### indicates that the blank control group is extremely significantly different from the negative control group. Detailed Implementation
[0027] This invention discloses the application of dodderamine and / or 19α-hydroxyasiatic acid. Those skilled in the art can refer to the content of this document and appropriately modify the process parameters to achieve the desired results. It is particularly important to note that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in this invention. The methods and applications of this invention have been described through preferred embodiments. Those skilled in the art can clearly modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit, and scope of this invention to realize and apply the technology of this invention.
[0028] This invention studies the anti-osteoporosis effects of eight chemical components—osthole, hyperin, epimedin C, icariin, schisandrin, cuscutamine, magnoflorine, and 19α-hydroxyasiatic acid—and their use as quality markers for the anti-osteoporosis effects of Bazibu Shen Capsules. Experimental results show that cuscutamine and 19α-hydroxyasiatic acid have anti-osteoporosis effects and can be used as quality markers for the anti-osteoporosis effects of Bazibu Shen Capsules.
[0029] Experimental materials and methods:
[0030] Instruments and reagents:
[0031] The samples were measured on the Waters ACQUITY UPLC I-Class Plus system, which is equipped with an autosampler, an online degasser, a binary solvent delivery system, and a Waters Xevo G2-XS QTOF with an ESI interface.
[0032] The following ingredients were supplied by Shijiazhuang Yiling Pharmaceutical Co., Ltd. of China: Cuscuta chinensis, Lycium barbarum, Schisandra chinensis, Cnidium monnieri, Rosa laevigata, Rubus idaeus, Melia toosendan, Allium tuberosum, Epimedium brevicornu, Morinda officinalis, Cistanche deserticola, Rehmannia glutinosa, Achyranthes bidentata, Panax ginseng, deer antler, seahorse, and 10 batches of Bazi Bushen Capsules.
[0033] Monotropein, deacetylaspelurosidic acid, rehmannioside D, echinacoside, cyasterone, xanthotoxol, isopimpinellin, xanthotoxin, toosendanin, 19α-hydroxyasiatic acid, rubiadin-1-methyl ether, schisandrin, schisandrol B, imperatorin, osthole, schisantherin A, schisantherin B, schisandrin A, cuscutamine, schisandrin B, kaempferol 3-O-rutinoside, kaempferol, isochlorogenic acid C, isoquercitrin were purchased from Chengdu Pusi Biotechnology Co., Ltd. Nystose, ginsenoside Rg2, ginsenoside Rc, ginsenoside Rb2, icariin, epimedin A, epimedin B, epimedin C, icariside I, icariside II, icariin, betaine, magnoflorine, neochlorogenic acid, and chlorogenic acid were purchased from Shanghai Ronghe Pharmaceutical Technology Co., Ltd. Hyperin, gallic acid, ellagic acid, ginsenoside Rb1, and γ-Glctamyl-S-allylcysteine were purchased from Chengdu Purifa Technology Development Co., Ltd. Ferulic acid, astragalin, azelaic acid, ginsenoside Re, ginsenoside Ro, and ginsenoside Rd were purchased from Chengdu Kloma Co., Ltd. Adenine and 6-hydroxypurine were purchased from Shanghai Maclean Biotechnology Co., Ltd. Ginsenoside Rg1 and quercetin were purchased from Chengdu Efa Biotechnology Co., Ltd. Acteoside was purchased from Anhui Zesheng Technology Co., Ltd. The purity of all reference standards was ≥98% as determined by HPLC.
[0034] Mass spectrometry water (HPLC grade) was purchased from Beijing Watsons Distilled Water Co., Ltd.; mass spectrometry grade methanol and acetonitrile were purchased from Thermo Fisher Scientific, USA; mass spectrometry grade formic acid was purchased from Sigma Aldrich, USA; other reagents were analytical grade and purchased from the market.
[0035] In the application of dodderamine and / or 19α-hydroxyasiatic acid provided by this invention, the raw materials and reagents used can all be purchased from the market.
[0036] The present invention will be further illustrated below with reference to the embodiments:
[0037] Example 1: Experimental animals and dosage of Bazi Bushen (a traditional Chinese medicine)
[0038] Female Sprague-Dawley rats (220±20g) were obtained from the Guangdong Provincial Laboratory Animal Center (Guangzhou). The experimental protocol was reviewed and approved by the Laboratory Animal Ethics Committee of Jinan University (IACUC-20220625-01). All experimental procedures complied with the "Guidelines for the Feeding and Use of Laboratory Animals" (Jinan University). Rats were housed in an environmentally controlled animal room (22-25℃, relative humidity 50-60%, 12-hour light-dark cycle) and fed a normal diet for two weeks prior to the experiment. Bazibu Shen capsules were dissolved in sterile water and administered by gavage at a dose of 0.2g / mL; 8 rats (Bazibu Shen group) were administered the drug by gavage for 3 consecutive days at a dose of 1g / kg / day; the remaining 2 rats (blank group) were administered an equal volume of sterile water by gavage.
[0039] Example 2 Sample Collection and Pretreatment Method
[0040] Whole blood samples were collected at 0.5 hours, 1 hour, 2 hours, and 4 hours after the last administration of the Bazibu Shen group in Example 1. After centrifugation at 13,200 rpm (10°C) for 10 minutes, the blood samples were separated into clean test tubes to obtain the Bazibu Shen group plasma samples, which were stored at -80°C for drug analysis. Blank plasma samples were obtained from the blank group rats using the same method.
[0041] Add three times the volume of acetonitrile to 2 mL of plasma sample, vortex, and centrifuge at 13200 rpm (10 °C) for 10 minutes. Dry the supernatant with nitrogen. Redissolve the residue in 200 μL of methanol, vortex, and then centrifuge at 13200 rpm (10 °C) for 20 minutes.
[0042] Example 3 Instrumental Analysis Conditions
[0043] Liquid chromatography conditions: Chromatographic separation was performed using an ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm, 1.7 μm) at a temperature of 35 °C. The mobile phase consisted of 0.1% (v / v) formic acid (phase A) and 0.1% (v / v) formic acid acetonitrile (phase B). Flow rate: 0.4 mL / min; elution gradient: 0–3.5 min, 2%–15% B; 3.5–12.5 min, 15%–36% B; 12.5–19.5 min, 36%–55% B; 19.5–23.5 min, 55%–80% B; 23.5–26 min, 80%–100% B; 26–28 min, 100% B; 28–29 min, 100%–2% B; 29–30 min, 2% B. Injection volume: 2 μL.
[0044] Mass spectrometry conditions: mass range 50-1500 Da; capillary voltage 3.0 kV (ESI) + The ion source temperature was 140℃; the desolvation gas temperature was 500℃; the backflush gas flow rate was 50 L / h; the desolvation gas flow rate was 1000 L / h; the low-channel collision energy was 6-30 eV, and the high-channel collision energy was 40-90 V; when the TIC intensity exceeded 5000 intensity / s, it automatically switched to MS / MS mode and switched back to MS scan after five MS / MS scans; the MS and MS / MS investigation scan times were both set to 0.2. In one MS scan, the five ions with the highest response were automatically selected for MS / MS. The mass accuracy was corrected using a leucine-enkephalin solution internal standard (m / z 556.2771 [M+H] in positive ion mode). + In negative ion mode, m / z 554.2615 [MH]-). LockSpray TM The flow rate was 5 μL / min, and data were collected using MassLynx 4.2 software (Waters, Milford, MA, USA).
[0045] Example 4: Results of in vivo metabolism experiment in rat plasma
[0046] According to the analytical method described in Example 3, 26 precursor substances (13 lignans, 5 coumarins, 3 alkaloids, 1 triterpenoid, 1 organic acid, and 3 other substances) were detected in the plasma of rats after oral administration of Bazibu Shen capsules. Among them, 11 precursor components, such as magnoflorine, cuscutamine, 19α-hydroxyasiatic acid, schisandrin, imperatorin, osthole, isopimpinellin, xanthotoxin, schisantherin A, schisantherin B, and schisandrin B, were confirmed by comparison with standards. According to Metabolynx... TM The software processed the data and used a Quality Defect Filter (MDF) to identify metabolites. The structures of several characteristic components were input into Metabolynx as parent components. TM In the software, metabolites such as icaritin, hyperin, rutin, osthole, xanthotoxin, schisandrin, schisantherin A, monotropein, echinacoside, cuscutamine, cyasterone, ginsenoside Rg1, and ginsenoside Rb1 were identified. Through precise mass, characteristic ion, and neutral loss analysis, the characteristics of 16 metabolites (3 isopentenyl flavonoids, 2 flavonols, 5 coumarins, and 6 lignans) of rutin, hyperin, icaritin, icariside II, osthole, and schisantherin A were preliminarily determined. The main metabolic pathways were oxidation, demethylation, hydrolysis, sulfation, and glucuronidation. Extracted ion chromatograms (EICs) of the original and metabolites in the plasma of rats after oral administration of Bazibu Shen capsules are shown below. Figure 1 Detailed UPLC-Q-TOF-MS data for the prototype are shown in Table 1. Detailed UPLC-Q-TOF-MS data for the metabolites are shown in Table 2.
[0047] It is noteworthy that epimedin C, icariin, icariside II, icaritin, rutin, and hyperin were not detected in vivo after oral administration of Bazibu Shen capsules. However, interestingly, their glucuronic acid metabolites (M1-M5) were detected in plasma. Therefore, magnoflorine, cuscutamine, 19α-hydroxyasiatic acid, imperatorin, osthole, isopimpinellin, xanthotoxin, schisandrin, schisantherin A, schisantherin B, schisandrin B, epimedin C, icariin, icariside II, icaritin, rutin, and hyperin were selected as absorbable candidate components.
[0048] Table 1. Characterization of the original form of Bazibu Shen capsules in rat plasma after oral administration
[0049]
[0050]
[0051] Table 2. Characteristics of metabolites in rat plasma after oral administration of Bazibu Shen capsules
[0052]
[0053]
[0054] Example 5: Osteoblast Differentiation Activity
[0055] Mouse embryonic osteogenic progenitor cells MC3T3-E1 were purchased from ATCC (American Academy of Sciences). Cells were cultured in α-MEM medium (Gibco, USA) with 1% P / S (100 units / mL penicillin, 100 mg / mL streptomycin) and 10% FBS (Gibco, USA) at 5% CO2, 37°C, and 95% humidity. After confluence, cell counts were performed using a Beckman Coulter cell counter, and cells were then seeded into 12-well plates, with each well containing 1.2 × 10⁻⁶ cells. 40.5 mL of α-MEM cell culture medium (1% P / S and 10% FBS) was used to culture each cell in adherent medium. Once the cells reached over 80% confluence, the medium was discarded and replaced with α-MEM (1% P / S, 10% FBS) osteogenic differentiation induction medium containing mineralization inducers (10 mM β-glycerophosphate sodium, 50 μg / m ascorbic acid). Specifically, 0.5 mL of the above osteogenic differentiation induction medium was added to 0.5 μL of the following solutions: blank solvent (anhydrous ethanol), 10 μM positive control 17β-estradiol, 0.1 μM, 1 μM, and 10 μM cuscutamine, and 0.1 μM, 1 μM, and 10 μM 19α-hydroxyasiatic acid. The cells were co-cultured for 7 days, with the drug-containing induction medium replaced every 2–3 days.
[0056] On day 8, the old drug-containing induction medium was discarded. Each well was then rinsed twice with 0.5 mL of PBS (0.01 M, pH 7.4, hereinafter the same), followed by 100 μL of Passive Lysis Buffer and lysed on ice with shaking for 30 min. First, 20 μL of cell lysis buffer was taken from each well and the procedure was performed according to the instructions on the Wako lab assay ALP detection kit (purchased from Wako, Japan). The OD value was then measured at 405 nm using a microplate reader. Simultaneously, 2 μL of cell lysis buffer was taken from each well and the procedure was performed according to the instructions on the BCA protein concentration detection kit (purchased from Shanghai Jining Industrial Co., Ltd.). The total protein content of each well was measured at 562 nm. Alkaline phosphatase (ALP) activity was expressed as an OD ratio: OD per well. ALP Value / OD per well BCA The relative activity of alkaline phosphatase was expressed as: OD ratio of each well × 100% / average OD ratio of the blank solvent control group. The experiment was repeated at least three times. Statistical analysis was performed using ANOVA, and p < 0.05 was considered statistically significant.
[0057] Example 6 Osteoblast mineralization activity
[0058] MC3T3-E1 cells were counted using a Beckman Coulter cell counter, and then seeded into 12-well plates, with each well containing 1×10⁻⁶ cells. 51.0 mL of α-MEM cell culture medium (1% P / S and 10% FBS) was used to culture cells until they adhered and reached 80% confluence. The medium was then replaced with fresh osteogenic differentiation induction medium for inducing mineralized calcium nodules. The specific drug addition was as follows: 1 mL of differentiation induction medium was added to 1 μL of the following solutions: blank solvent (anhydrous ethanol), 10 μM positive control 17β-estradiol, 0.1 μM, 1 μM, and 10 μM cuscutamine, and 0.1 μM, 1 μM, and 10 μM 19α-hydroxyasiatic acid. The cells were co-cultured for approximately 30 days, with fresh drug-containing induction medium added every 2–3 days until mineralized calcium nodules were observed. After terminating the culture, the old culture medium was discarded, and the cells were gently washed twice with 0.5 mL of PBS. Then, 300 μL of 4% paraformaldehyde solution was added to each well for fixation for 15 minutes. Finally, Alizarin Red S staining was used for qualitative observation.
[0059] The specific staining steps were as follows: after washing each well once with 0.5 mL of PBS, 0.5 mL of 1% Alizarin Red S staining solution was added for 10 minutes. Then, the plates were repeatedly rinsed with double-distilled water until the background color was removed. After the plates were air-dried, photographs were taken for qualitative observation and comparison. To further quantify the formation of mineralized calcium nodules, 500 μL of 0.5 M HCl-5% SDS solution (pH 3-4) was added to each well, and the mineralized calcium nodules were continuously shaken and dissolved for 30 minutes. Finally, 200 μL of the dissolved solution was transferred from each well to a 96-well plate, and the OD value was detected at a wavelength of 415 nm using a microplate reader. The promotion rate of mineralized calcium nodules was characterized by OD value × 100% / the average OD value of the blank solvent control group. The experiment was repeated at least three times for statistical analysis. Experimental data were analyzed using the ANOVA test, with p < 0.05 considered statistically significant.
[0060] Example 7: Osteoclast Differentiation Activity
[0061] Mouse RAW264.7 cells were obtained from the American Type Culture Collection (ATCC) and routinely cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS), 100 U / mL penicillin, and 100 μg / mL streptomycin at 37°C, 95% humidity, and 5% CO2. Subculture was performed every two to three days.
[0062] To investigate the effects of cuscutamine and 19α-hydroxyasiatic acid on cytotoxicity, RAW264.7 cells were seeded into 96-well plates at a density of 3000 cells / well. After 24 hours, cells were incubated with different concentrations of cuscutamine and 19α-hydroxyasiatic acid (10...-7 -10 -5 Cells were treated with differentiation medium or blank solvent (0.1% DMSO) for four days for cytotoxicity assays, with the medium changed every two days. After the above treatment, cytotoxicity was determined using a CCK-8 assay kit (Dojindo, Kumamoto, Japan) according to the manufacturer's instructions. Absorbance at 450 nm was measured using a multi-mode microplate reader (BioTEK Synergy H1 Hybrid Multi-Mode Reader, USA).
[0063] RAW 264.7 cells were seeded in 96-well plates at a density of 3000 cells / well. Then, the plates were treated with a solution containing blank solvent (0.1% DMSO), cuscutamine, and 19α-hydroxyasiatic acid (10...). -7 -10 -5 Cells were induced for 4 days in differentiation medium (αMEM, 10% FBS, containing 30 ng / mL M-CSF and 100 ng / mL sRANKL). Cells were then fixed and stained with anti-tartrate phosphatase (TRAP) using a leukocyte acid phosphatase kit (Sigma, USA). TRAP-positive cells with more than three nuclei were considered mature osteoclasts. Experimental data were statistically analyzed using ANOVA, with p < 0.05 considered statistically significant. All statistical analyses were performed using GraphPad Prism (version 6.0, GraphPad Software, USA).
[0064] Example of effect
[0065] The anti-osteoporosis effects of cuscutamine and 19α-hydroxyasiatic acid in mouse MC3T3-E1 cells and their osteoclast differentiation (TRAP-positive cell number) in sRANKL-induced mouse RAW 264.7 macrophages were assessed using osteoblast differentiation (ALP) and mineralization (Alizarin Red stained calcified nodules). Figure 2 As shown, cuscutamine (10 -6 M),19α-hydroxyasiatic acid(10 -6 and 10 -5 M) significantly promoted ALP activity (P<0.05). For example... Figure 3 A and Figure 3 As shown in B, cuscutamine at 10 -6 M significantly promoted the formation of calcified bone nodules (P<0.05). For example... Figure 4 A and Figure 4As shown in B, cuscutamine (10 -5 M),19α-hydroxyasiatic acid(10 -7 and 10 -6 M) significantly reduced the number of multinucleated TRAP-positive cells (P<0.05). These results indicate that cuscutamine and 19α-hydroxyasiatic acid possess anti-osteoporosis activity in osteoblast or osteoclast activity evaluation systems.
[0066] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. Application of Cuscutaamine as the sole active ingredient in the preparation of drugs for treating osteoporosis.
2. The application as described in claim 1, characterized in that, The anti-osteoporosis measures include: (I) Promotes osteoblast differentiation; (II) Promotes bone calcification nodules; and / or (III) Inhibit osteoclast differentiation.
3. The application as described in claim 1 or 2, characterized in that, The effective concentration of the dodderamine is 10. -7 M~10 -5 M.
